Cartalax

Cartalax is a synthetic tripeptide, Ala-Glu-Asp (AED, T-31), from the Khavinson bioregulator programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a cytogen: a short synthetic peptide with tissue tropism intended to normalise cellular function in the target tissue. Vladimir Khavinson (1946 to 2024) directed the institute and served as Vice-President of the Gerontological Society of the Russian Academy of Sciences; the programme's premise is that short peptides derived from healthy tissue restore function in aged or damaged cells by normalising gene expression.

Despite the name and its marketing for joint health, the primary target is the fibroblast, present across cartilage, skin, vasculature, kidney, tendon and ligament. Chondrocyte tropism is also described, and because chondrocytes share structural and functional features with fibroblasts the fibroblast data are taken as relevant to cartilage. Stated applications span regenerative medicine, rheumatology, sports medicine and age-management, with specific suitability claimed for osteoarthritis, chondropathy and degenerative joint disease.

At three residues it is among the smallest bioactive peptides studied for tissue regeneration. The mechanism proposed bypasses surface receptors entirely: membrane and nuclear penetration with direct DNA interaction and epigenetic modulation of transcription. Chain length is also the basis for its claimed low immunogenicity.

Regulatory and evidential status: not FDA approved, no completed human trials, research compound only. The evidence base is peer-reviewed but comes almost entirely from the developing laboratory, with no independent Western replication.

Presentation: 20 mg lyophilised vial, reconstituted with bacteriostatic water, subcutaneous, on 10 to 20 day courses repeated 3 to 4 times yearly.

Cartalax is also the largest component by mass in the BPC-157 + TB-500 + Cartalax blend on this site; that entry carries its own dosing and notes that no separate information is available about the Cartalax arm.

Cartalax is proposed to act without a surface receptor. The tripeptide crosses the plasma membrane and nuclear envelope and binds DNA in the minor groove, preferentially at AT-rich sequences such as d(ATATATATAT)2. Binding is said to alter chromatin structure and transcription factor access, shifting the transcriptional profile toward a more youthful pattern. This is framed as epigenetic regulation of gene expression rather than signalling cascade activation. Khavinson et al. (2021), a systematic review in Molecules, supplies the theoretical framework for sequence-specific DNA binding by short peptides across taxa, though it is authored by the developing group.

Fibroblast regulation, from Linkova et al. (2016) in skin fibroblast cultures during in vitro ageing: increased Ki-67 (proliferation), with the effect most marked in aged cultures where Ki-67 normally declines; increased CD98hc, a regeneration-associated glycoprotein that falls with age; suppressed caspase-3 activity, reducing apoptosis in both young and aged cultures; and inhibited MMP-9 synthesis, limiting extracellular matrix degradation. The anti-catabolic MMP-9 effect is the mechanistic link to cartilage matrix preservation.

Senescence modulation, from Khavinson et al. (2014) in renal cell cultures from young and aged rats: decreased p16, p21 and p53 expression, increased SIRT-6, and increased proliferation, attributed to the same minor-groove DNA binding.

The compound is characterised as a normaliser with bidirectional effect, enhancing underactive processes and damping overactive ones, distinct from single-pathway agonism or antagonism. Whether this reflects selective regulation or measurement artefact is unresolved pending independent replication. No binding affinity data accompany the claims.

The mechanism is a combined anabolic and anti-catabolic account of connective tissue matrix turnover: enhanced fibroblast and chondrocyte activity supporting collagen, elastin and proteoglycan synthesis; restored expression of genes governing cartilage growth and maintenance; and reduced matrix breakdown under mechanical stress or ageing via MMP-9 inhibition. Limited animal research indicates chondrocyte proliferation in both young and old animals, though this is less well characterised than the fibroblast and renal work.

Structural outcomes: maintenance of cartilage density and elasticity; slowed or prevented cartilage degeneration; slowed progression of osteoarthritis and other degenerative joint disease; protection against age-related cartilage breakdown.

Symptomatic: mitigation of chronic joint pain and inflammation; reduced stiffness associated with degenerative change; possible reduction of cytokine-driven intra-articular inflammation.

Functional: improved joint mobility and flexibility; enhanced tissue resilience under high mechanical load; connective tissue resilience supporting posture and movement.

Recovery and protection: accelerated rehabilitation after sports injury or orthopaedic surgery; support for cartilage and ligament repair after trauma or surgery; protection of cartilage from excessive wear in athletes and physically demanding occupations.

Spinal: contribution to spinal health, particularly in age-related intervertebral disc degeneration.

Dermal and connective tissue, from Linkova et al. (2016): increased fibroblast proliferation in aged skin cultures, enhanced collagen and extracellular matrix production markers, reduced MMP-9 activity, improved regeneration markers, with the largest effects in aged cells.

Senescence, from Khavinson et al. (2014): decreased p53, p16 and p21, increased SIRT-6, reduced apoptosis in aged cultures. Kidney polypeptide isolates increased cell renewal in ageing rat kidneys, and Cartalax specifically raised proliferation markers while lowering senescence markers in renal cultures.

Positioning: a maintenance and anti-ageing compound for connective tissue rather than an acute healing agent, and a stated role in comprehensive musculoskeletal longevity programmes. Every outcome above derives from in vitro or animal models; no controlled human efficacy data exist.

No human clinical trials exist, so there are no controlled timepoint data. In vitro, shifts in Ki-67 and in p16, p21 and p53 appeared within standard experimental windows of days to weeks; translation to human dosing is unknown.

User-reported timelines, aggregated from a very small base of self-experimenters:

Days 1 to 7: no perceptible effect for most, consistent with an epigenetic rather than receptor-mediated mechanism.

Weeks 1 to 2: some report subtle improvements in joint comfort or mobility during training, including a sense of greater sturdiness under squatting and lifting patterns and the ability to increase loads. Others report nothing.

Weeks 2 to 3: responders describe gradual improvement in joint sturdiness and connective tissue comfort, with knee and hip discomfort the most frequently cited. One report described rapid improvement in nagging hip pain over 3 weeks at 2 mg per day.

Post-cycle: some users report persistence or continued development of benefit after a 10 to 20 day cycle, which would be consistent with the proposed mechanism but is unverified.

Non-response at standard doses is also reported. Absent human data, non-response cannot be distinguished from inadequate duration or product quality.

Effects are characterised as subtle rather than dramatic. The compound is positioned as maintenance for ageing connective tissue, not an acute healing agent, and the clear signal users associate with BPC-157 should not be expected. Given the sample size, placebo cannot be excluded for any reported benefit.

Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL (10,000 mcg/mL), 100 mcg per insulin unit. Add diluent down the vial wall and swirl; do not shake.

Draws: 2 mg = 20 units; 1 mg = 10 units.

Administration: subcutaneous, once daily. Morning administration is generally preferred, with consistent timing. No relationship to meals; no fasting requirement.

Standard protocol: 2 mg once daily for 10 to 20 days, repeated 3 to 4 times per year with a 3 to 4 month break between cycles. No titration: start at the standard dose. Dose is flat throughout the cycle. Short intensive cycles are preferred over continuous exposure on the rationale that transcriptional changes consolidate during the off period and persist beyond dosing.

A low-dose variant of 1 mg daily for 10 to 20 days has also been described. No selection criterion is given between dose levels or across the duration range. Exposure per course therefore spans 10 mg (1 mg for 10 days, half a vial) to 40 mg (2 mg for 20 days, two vials), a fourfold spread without guidance.

Effects are subtle and cumulative across the cycle; there is no acute response. Post-cycle persistence of benefit is proposed on mechanistic grounds and reported by some users but unverified.

No published dose-finding studies exist in humans. The protocol derives from the Khavinson research framework and practice.

Cross-product note: the BPC-157 + TB-500 + Cartalax blend on this site carries 10 mg of Cartalax per 20 mg vial, delivering 300 to 500 mcg of Cartalax per dose on its schedules, below the low-dose variant here. Concurrent use stacks the Cartalax arm.

The evidence base is preclinical, in vitro, and derived almost entirely from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. No human clinical trials exist, no dose-finding studies exist, and no independent Western replication has been published.

Linkova et al. (2016), Bulletin of Experimental Biology and Medicine: immunofluorescent confocal microscopy of skin fibroblasts during in vitro ageing. Cartalax increased Ki-67 (proliferation) and CD98hc (regeneration), decreased caspase-3 activity (apoptosis), and inhibited MMP-9 synthesis (matrix degradation). Effects were present in young and aged cultures, with greater magnitude in aged cells. Control description does not extend beyond untreated cells; the authors are the compound's developers.

Khavinson et al. (2014), Advances in Gerontology / Bulletin of Experimental Biology and Medicine: renal cell cultures from young and aged rats. Cartalax (AED) and EDL increased proliferation, decreased p16, p21, and p53 expression, and increased SIRT-6 expression. Mechanism attributed to minor-groove binding at AT-rich DNA sequences such as d(ATATATATAT)2, altering chromatin structure and transcription factor activity. Same group.

Khavinson et al. (2021), Molecules: systematic review of short-peptide regulation of gene expression across plants, microorganisms, insects, birds, rodents, primates, and humans. Provides the theoretical framework for DNA-binding tripeptide activity; same authorship.

Chondrocyte data: limited reports of stimulated chondrocyte proliferation in young and old animals, less well characterised than the fibroblast and renal work.

Interpretation: the marker changes are internally consistent and the proposed epigenetic mechanism is coherent, but the entire body of work sits within one laboratory ecosystem with controls that are limited by Western standards. Whether the 'normaliser' profile reflects genuine bidirectional regulation or an artefact of outcome measurement remains open. Biomarker shifts in culture do not establish clinical efficacy or safety in humans. The compound is not FDA approved.

Earlier guidance on this page framed Cartalax as chondrocyte-directed with clinical use in rheumatology and sports medicine; the primary target is in fact the fibroblast, with chondrocyte effects inferred from shared characteristics and limited animal data.